Literature DB >> 26576201

Myobacterium bovis peri-prosthetic hip infection with successful prosthesis retention following intravesical BCG therapy for bladder carcinoma.

Lucy Ping Aitchison1, Viran Jayanetti1, Steven T Lindstrom1, Ronald Sekel1.   

Abstract

Systemic dissemination and peri-prosthetic infection of Mycobacterium bovis (M. bovis) following intravesical Bacillus Calmette-Guerin (BCG) therapy presents a rare but significant complication of treatment for non-muscle invasive bladder carcinoma. We present a patient with Mycobacterium bovis infection of a prosthetic hip nine months following BCG therapy for bladder cancer. The debridement and (implant) prosthesis retention approach in conjunction with anti-tuberculous medication (DAIR) employed in this case, allowed the same prosthesis to be retained. This case report highlights the importance of physician awareness of the possibility BCG peri-prosthetic infections.

Entities:  

Keywords:  Intravesical BCG therapy; Mycobacterium bovis; non-muscle invasive urothelial carcinoma of the bladder; peri-prosthetic infection

Year:  2015        PMID: 26576201      PMCID: PMC4643607          DOI: 10.4066/AMJ.2015.2475

Source DB:  PubMed          Journal:  Australas Med J        ISSN: 1836-1935


  38 in total

Review 1.  The diagnosis and management of prosthetic joint infections.

Authors:  E Moran; I Byren; B L Atkins
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

2.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

Authors:  A Böhle; D Jocham; P R Bock
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial.

Authors:  A P van der Meijden; M Brausi; V Zambon; W Kirkels; C de Balincourt; R Sylvester
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

Review 4.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

Authors:  Marko Babjuk; Maximilian Burger; Richard Zigeuner; Shahrokh F Shariat; Bas W G van Rhijn; Eva Compérat; Richard J Sylvester; Eero Kaasinen; Andreas Böhle; Joan Palou Redorta; Morgan Rouprêt
Journal:  Eur Urol       Date:  2013-06-12       Impact factor: 20.096

5.  [Management, and prevention, of intravesical therapy complications].

Authors:  V Serretta
Journal:  Urologia       Date:  2009 Jan-Mar

Review 6.  Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.

Authors:  D L Lamm
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

Review 7.  Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

Authors:  M D Shelley; T J Wilt; J Court; B Coles; H Kynaston; M D Mason
Journal:  BJU Int       Date:  2004-03       Impact factor: 5.588

8.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

9.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

10.  Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment.

Authors:  D L Paterson; A Patel
Journal:  Aust N Z J Surg       Date:  1998-05
View more
  2 in total

1.  Mycobacterium bovis prosthetic joint infection following intravesical instillation of BCG for bladder cancer.

Authors:  Ashka Patel; Joel Elzweig
Journal:  BMJ Case Rep       Date:  2019-12-18

2.  Mycobacterium bovis infection of total hip arthroplasty after intravesicular Bacillus Calmette-Guérin.

Authors:  Ariane Williams; Brendan Arnold; David P Gwynne-Jones
Journal:  Arthroplast Today       Date:  2019-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.